Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies
We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m 2 /day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The...
Gespeichert in:
| Veröffentlicht in: | Chemotherapy (Basel) 2005-08, Vol.51 (5), p.247-251 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 251 |
|---|---|
| container_issue | 5 |
| container_start_page | 247 |
| container_title | Chemotherapy (Basel) |
| container_volume | 51 |
| creator | Robak, T. Szmigielska-Kapłon, A. Błoński, J.Z. Kasznicki, M. Chojnowski, K. |
| description | We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m 2 /day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The cycles were repeated every 28 days, reaching a maximum of six courses. Twenty patients entered the study. All patients had received three or more cycles of chemotherapy before the EC regimen (median 8, range 3–19). Thirteen patients received 2-CdA before the EC regimen. Seven out of 20 patients (35%) responded, including one complete response. Median overall survival time of responding patients was 22 months (range 3–30). Myelosuppression and infections were the major toxicity of the EC regimen. |
| doi_str_mv | 10.1159/000087251 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16088121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>886677281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-c2fb40d79bc2407f2e8e3d1081693bb87daf417fd6fb0a293e1072441a453ba53</originalsourceid><addsrcrecordid>eNpd0VFrFDEQAOAgir1WH3wWJAgKPqxmkuxm81iO1hZO7IM-L9nNpE3d3VyTXOX-vTn2aMF5GSZ8zIQZQt4B-wpQ62-sRKt4DS_ICiSHSistX5JVedaVgFqdkNOU7kspGgGvyQk0rG2Bw4o8nA_ZP_q8p8HR9Whs9L2fka7DdMiW_vX5jl7ksA3JW6R-pldoHv24pzcRc0STC7ox2eOc06KvZxvGUtLNftreBW_pDzP629nMg8f0hrxyZkz49pjPyO_Li1_rq2rz8_v1-nxTDUJDrgbuesms0v3AJVOOY4vCAmuh0aLvW2WNk6CcbVzPDNcCgSkuJRhZi97U4ox8XvpuY3jYYcrd5NOA42hmDLvUcaZZI1pe4Mf_4H3Yxbn8reNc8EbXQhX0ZUFDDClFdN02-snEfQesOxyhezpCsR-ODXf9hPZZHrdewKcjMGkwo4uHzaRnp5iSnIni3i_uj4m3GJ_AMuYfpwKXMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223269537</pqid></control><display><type>article</type><title>Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies</title><source>MEDLINE</source><source>Karger Journals</source><creator>Robak, T. ; Szmigielska-Kapłon, A. ; Błoński, J.Z. ; Kasznicki, M. ; Chojnowski, K.</creator><creatorcontrib>Robak, T. ; Szmigielska-Kapłon, A. ; Błoński, J.Z. ; Kasznicki, M. ; Chojnowski, K.</creatorcontrib><description>We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m 2 /day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The cycles were repeated every 28 days, reaching a maximum of six courses. Twenty patients entered the study. All patients had received three or more cycles of chemotherapy before the EC regimen (median 8, range 3–19). Thirteen patients received 2-CdA before the EC regimen. Seven out of 20 patients (35%) responded, including one complete response. Median overall survival time of responding patients was 22 months (range 3–30). Myelosuppression and infections were the major toxicity of the EC regimen.</description><identifier>ISSN: 0009-3157</identifier><identifier>EISSN: 1421-9794</identifier><identifier>DOI: 10.1159/000087251</identifier><identifier>PMID: 16088121</identifier><identifier>CODEN: CHTHBK</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Cladribine - administration & dosage ; Clinical Study ; Clinical trials ; Etoposide - administration & dosage ; Female ; Hematologic and hematopoietic diseases ; Humans ; Infection - chemically induced ; Infusions, Intravenous ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma ; Lymphoma, Non-Hodgkin - drug therapy ; Male ; Medical sciences ; Middle Aged ; Neutropenia - chemically induced ; Pharmacology. Drug treatments ; Recurrence ; Survival Analysis ; Treatment Outcome</subject><ispartof>Chemotherapy (Basel), 2005-08, Vol.51 (5), p.247-251</ispartof><rights>2005 S. Karger AG, Basel</rights><rights>2005 INIST-CNRS</rights><rights>Copyright 2005 S. Karger AG, Basel.</rights><rights>Copyright (c) 2005 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-c2fb40d79bc2407f2e8e3d1081693bb87daf417fd6fb0a293e1072441a453ba53</citedby><cites>FETCH-LOGICAL-c391t-c2fb40d79bc2407f2e8e3d1081693bb87daf417fd6fb0a293e1072441a453ba53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17074203$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16088121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robak, T.</creatorcontrib><creatorcontrib>Szmigielska-Kapłon, A.</creatorcontrib><creatorcontrib>Błoński, J.Z.</creatorcontrib><creatorcontrib>Kasznicki, M.</creatorcontrib><creatorcontrib>Chojnowski, K.</creatorcontrib><title>Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies</title><title>Chemotherapy (Basel)</title><addtitle>Chemotherapy</addtitle><description>We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m 2 /day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The cycles were repeated every 28 days, reaching a maximum of six courses. Twenty patients entered the study. All patients had received three or more cycles of chemotherapy before the EC regimen (median 8, range 3–19). Thirteen patients received 2-CdA before the EC regimen. Seven out of 20 patients (35%) responded, including one complete response. Median overall survival time of responding patients was 22 months (range 3–30). Myelosuppression and infections were the major toxicity of the EC regimen.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Cladribine - administration & dosage</subject><subject>Clinical Study</subject><subject>Clinical trials</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Infection - chemically induced</subject><subject>Infusions, Intravenous</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neutropenia - chemically induced</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0009-3157</issn><issn>1421-9794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0VFrFDEQAOAgir1WH3wWJAgKPqxmkuxm81iO1hZO7IM-L9nNpE3d3VyTXOX-vTn2aMF5GSZ8zIQZQt4B-wpQ62-sRKt4DS_ICiSHSistX5JVedaVgFqdkNOU7kspGgGvyQk0rG2Bw4o8nA_ZP_q8p8HR9Whs9L2fka7DdMiW_vX5jl7ksA3JW6R-pldoHv24pzcRc0STC7ox2eOc06KvZxvGUtLNftreBW_pDzP629nMg8f0hrxyZkz49pjPyO_Li1_rq2rz8_v1-nxTDUJDrgbuesms0v3AJVOOY4vCAmuh0aLvW2WNk6CcbVzPDNcCgSkuJRhZi97U4ox8XvpuY3jYYcrd5NOA42hmDLvUcaZZI1pe4Mf_4H3Yxbn8reNc8EbXQhX0ZUFDDClFdN02-snEfQesOxyhezpCsR-ODXf9hPZZHrdewKcjMGkwo4uHzaRnp5iSnIni3i_uj4m3GJ_AMuYfpwKXMw</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>Robak, T.</creator><creator>Szmigielska-Kapłon, A.</creator><creator>Błoński, J.Z.</creator><creator>Kasznicki, M.</creator><creator>Chojnowski, K.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200508</creationdate><title>Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies</title><author>Robak, T. ; Szmigielska-Kapłon, A. ; Błoński, J.Z. ; Kasznicki, M. ; Chojnowski, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-c2fb40d79bc2407f2e8e3d1081693bb87daf417fd6fb0a293e1072441a453ba53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Cladribine - administration & dosage</topic><topic>Clinical Study</topic><topic>Clinical trials</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Infection - chemically induced</topic><topic>Infusions, Intravenous</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neutropenia - chemically induced</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robak, T.</creatorcontrib><creatorcontrib>Szmigielska-Kapłon, A.</creatorcontrib><creatorcontrib>Błoński, J.Z.</creatorcontrib><creatorcontrib>Kasznicki, M.</creatorcontrib><creatorcontrib>Chojnowski, K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Chemotherapy (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robak, T.</au><au>Szmigielska-Kapłon, A.</au><au>Błoński, J.Z.</au><au>Kasznicki, M.</au><au>Chojnowski, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies</atitle><jtitle>Chemotherapy (Basel)</jtitle><addtitle>Chemotherapy</addtitle><date>2005-08</date><risdate>2005</risdate><volume>51</volume><issue>5</issue><spage>247</spage><epage>251</epage><pages>247-251</pages><issn>0009-3157</issn><eissn>1421-9794</eissn><coden>CHTHBK</coden><abstract>We determined the effectiveness and toxicity of combined chemotherapy consisting of etoposide 100 mg/m 2 /day i.v. and cladribine (2-CdA) 0.12 mg/kg/day i.v. each for 5 days (EC regimen) in the treatment of refractory or relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The cycles were repeated every 28 days, reaching a maximum of six courses. Twenty patients entered the study. All patients had received three or more cycles of chemotherapy before the EC regimen (median 8, range 3–19). Thirteen patients received 2-CdA before the EC regimen. Seven out of 20 patients (35%) responded, including one complete response. Median overall survival time of responding patients was 22 months (range 3–30). Myelosuppression and infections were the major toxicity of the EC regimen.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>16088121</pmid><doi>10.1159/000087251</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-3157 |
| ispartof | Chemotherapy (Basel), 2005-08, Vol.51 (5), p.247-251 |
| issn | 0009-3157 1421-9794 |
| language | eng |
| recordid | cdi_pubmed_primary_16088121 |
| source | MEDLINE; Karger Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Cladribine - administration & dosage Clinical Study Clinical trials Etoposide - administration & dosage Female Hematologic and hematopoietic diseases Humans Infection - chemically induced Infusions, Intravenous Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma Lymphoma, Non-Hodgkin - drug therapy Male Medical sciences Middle Aged Neutropenia - chemically induced Pharmacology. Drug treatments Recurrence Survival Analysis Treatment Outcome |
| title | Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A16%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20Cladribine%20Combined%20with%20Etoposide%20in%20Heavily%20Pretreated%20Patients%20with%20Indolent%20Lymphoid%20Malignancies&rft.jtitle=Chemotherapy%20(Basel)&rft.au=Robak,%20T.&rft.date=2005-08&rft.volume=51&rft.issue=5&rft.spage=247&rft.epage=251&rft.pages=247-251&rft.issn=0009-3157&rft.eissn=1421-9794&rft.coden=CHTHBK&rft_id=info:doi/10.1159/000087251&rft_dat=%3Cproquest_pubme%3E886677281%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223269537&rft_id=info:pmid/16088121&rfr_iscdi=true |